Abstract
CNS disease, or central neuropsychiatric lupus erythematosus (cNPSLE), occurs frequently in pediatric lupus, leading to significant morbidity and poor long-term outcomes. Diagnosing cNPSLE is especially difficult in pediatrics; many current diagnostic tools are invasive and/or costly, and there are no current accepted screening mechanisms. The most complicated aspect of diagnosis is differentiating primary disease from other etiologies; research to discover new biomarkers is attempting to address this dilemma. With many mechanisms involved in the pathogenesis of cNPSLE, biomarker profiles across several modalities (molecular, psychometric and neuroimaging) will need to be used. For the care of children with lupus, the challenge will be to develop biomarkers that are accessible by noninvasive measures and reliable in a pediatric population.
| Original language | English |
|---|---|
| Pages (from-to) | 545-558 |
| Number of pages | 14 |
| Journal | Biomarkers in Medicine |
| Volume | 9 |
| Issue number | 6 |
| DOIs | |
| State | Published - 1 Jun 2015 |
| Externally published | Yes |
Bibliographical note
Publisher Copyright:© 2015 Future Medicine Ltd.
Funding
| Funders | Funder number |
|---|---|
| National Institutes of Health | |
| National Institute of Arthritis and Musculoskeletal and Skin Diseases | R01AR065594 |
Keywords
- CNS
- biomarkers
- neuropsychiatric
- pediatric
- systemic lupus erythematosus